Search Results - "Frampton, M."

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers by Goodman, Aaron M, Kato, Shumei, Bazhenova, Lyudmila, Patel, Sandip P, Frampton, Garrett M, Miller, Vincent, Stephens, Philip J, Daniels, Gregory A, Kurzrock, Razelle

“…Immunotherapy induces durable responses in a subset of patients with cancer. High tumor mutational burden (TMB) may be a response biomarker for PD-1/PD-L1…”
Get full text

Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors by Milbury, Coren A, Creeden, James, Yip, Wai-Ki, Smith, David L, Pattani, Varun, Maxwell, Kristi, Sawchyn, Bethany, Gjoerup, Ole, Meng, Wei, Skoletsky, Joel, Concepcion, Alvin D, Tang, Yanhua, Bai, Xiaobo, Dewal, Ninad, Ma, Pei, Bailey, Shannon T, Thornton, James, Pavlick, Dean C, Frampton, Garrett M, Lieber, Daniel, White, Jared, Burns, Christine, Vietz, Christine

“…FoundationOne®CDx (F1CDx) is a United States (US) Food and Drug Administration (FDA)-approved companion diagnostic test to identify patients who may benefit…”
Get full text

A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal by Sun, James X, He, Yuting, Sanford, Eric, Montesion, Meagan, Frampton, Garrett M, Vignot, Stéphane, Soria, Jean-Charles, Ross, Jeffrey S, Miller, Vincent A, Stephens, Phil J, Lipson, Doron, Yelensky, Roman

“…A key constraint in genomic testing in oncology is that matched normal specimens are not commonly obtained in clinical practice. Thus, while well-characterized…”
Get full text

Psychological distress and psychiatric disorder after natural disasters: systematic review and meta-analysis by Beaglehole, Ben, Mulder, Roger T., Frampton, Chris M., Boden, Joseph M., Newton-Howes, Giles, Bell, Caroline J.

“…Natural disasters are increasing in frequency and severity. They cause widespread hardship and are associated with detrimental effects on mental health.AimsOur…”
Get full text

Betaine and Trimethylamine-N-Oxide as Predictors of Cardiovascular Outcomes Show Different Patterns in Diabetes Mellitus: An Observational Study by Lever, Michael, George, Peter M, Slow, Sandy, Bellamy, David, Young, Joanna M, Ho, Markus, McEntyre, Christopher J, Elmslie, Jane L, Atkinson, Wendy, Molyneux, Sarah L, Troughton, Richard W, Frampton, Christopher M, Richards, A Mark, Chambers, Stephen T

“…Betaine is a major osmolyte, also important in methyl group metabolism. Concentrations of betaine, its metabolite dimethylglycine and analog…”
Get full text

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden by Chalmers, Zachary R, Connelly, Caitlin F, Fabrizio, David, Gay, Laurie, Ali, Siraj M, Ennis, Riley, Schrock, Alexa, Campbell, Brittany, Shlien, Adam, Chmielecki, Juliann, Huang, Franklin, He, Yuting, Sun, James, Tabori, Uri, Kennedy, Mark, Lieber, Daniel S, Roels, Steven, White, Jared, Otto, Geoffrey A, Ross, Jeffrey S, Garraway, Levi, Miller, Vincent A, Stephens, Phillip J, Frampton, Garrett M

“…High tumor mutational burden (TMB) is an emerging biomarker of sensitivity to immune checkpoint inhibitors and has been shown to be more significantly…”
Get full text

Enhancer decommissioning by LSD1 during embryonic stem cell differentiation by Whyte, Warren A., Bilodeau, Steve, Orlando, David A., Hoke, Heather A., Frampton, Garrett M., Foster, Charles T., Cowley, Shaun M., Young, Richard A.

“…In embryonic stem cells, the histone demethylase LSD1 occupies the enhancers of active genes and, together with the NuRD complex, decommissions the enhancers…”
Get full text

Histone H3K27ac separates active from poised enhancers and predicts developmental state by Creyghton, Menno P., Cheng, Albert W., Welstead, G. Grant, Kooistra, Tristan, Carey, Bryce W., Steine, Eveline J., Hanna, Jacob, Lodato, Michael A., Frampton, Garrett M., Sharp, Phillip A., Boyer, Laurie A., Young, Richard A., Jaenisch, Rudolf

“…Developmental programs are controlled by transcription factors and chromatin regulators, which maintain specific gene expression programs through epigenetic…”
Get full text

PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers by Yarchoan, Mark, Albacker, Lee A, Hopkins, Alexander C, Montesion, Meagan, Murugesan, Karthikeyan, Vithayathil, Teena T, Zaidi, Neeha, Azad, Nilofer S, Laheru, Daniel A, Frampton, Garrett M, Jaffee, Elizabeth M

“…PD-L1 expression and tumor mutational burden (TMB) have emerged as important biomarkers of response to immune checkpoint inhibitor (ICI) therapy. These…”
Get full text

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial by Rosenberg, Jonathan E, Dr, Hoffman-Censits, Jean, MD, Powles, Tom, Prof, van der Heijden, Michiel S, Prof, Balar, Arjun V, MD, Necchi, Andrea, MD, Dawson, Nancy, Prof, O'Donnell, Peter H, MD, Balmanoukian, Ani, MD, Loriot, Yohann, MD, Srinivas, Sandy, MD, Retz, Margitta M, Prof, Grivas, Petros, MD, Joseph, Richard W, MD, Galsky, Matthew D, MD, Fleming, Mark T, MD, Petrylak, Daniel P, Prof, Perez-Gracia, Jose Luis, MD, Burris, Howard A, MD, Castellano, Daniel, MD, Canil, Christina, MD, Bellmunt, Joaquim, MD, Bajorin, Dean, Prof, Nickles, Dorothee, PhD, Bourgon, Richard, PhD, Frampton, Garrett M, PhD, Cui, Na, PhD, Mariathasan, Sanjeev, PhD, Abidoye, Oyewale, MD, Fine, Gregg D, MD, Dreicer, Robert, Prof

“…Summary Background Patients with metastatic urothelial carcinoma have few treatment options after failure of platinum-based chemotherapy. In this trial, we…”
Get full text

Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response by Montesion, Meagan, Murugesan, Karthikeyan, Jin, Dexter X, Sharaf, Radwa, Sanchez, Nora, Guria, Ameet, Minker, Max, Li, Gerald, Fisher, Virginia, Sokol, Ethan S, Pavlick, Dean C, Moore, Jay A, Braly, Alan, Singal, Gaurav, Fabrizio, David, Comment, Leah A, Rizvi, Naiyer A, Alexander, Brian M, Frampton, Garrett M, Hegde, Priti S, Albacker, Lee A

“…Neoantigen presentation arises as a result of tumor-specific mutations and is a critical component of immune surveillance that can be abrogated by somatic LOH…”
Get more information

The lifetime risk of revision following total hip arthroplasty: a New Zealand Joint Registry study by Young, Simon W, Frampton, Christopher M, Hooper, Gary J

“…AimsJoint registries typically use revision of an implant as an endpoint and report survival rates after a defined number of years. However, reporting lifetime…”
Get full text

Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC by Riess, Jonathan W, Gandara, David R, Frampton, Garrett M, Madison, Russell, Peled, Nir, Bufill, Jose A, Dy, Grace K, Ou, Sai-Hong Ignatius, Stephens, Philip J, McPherson, John D, Lara, Jr, Primo N, Burich, Rebekah A, Ross, Jeffrey S, Miller, Vincent A, Ali, Siraj M, Mack, Philip C, Schrock, Alexa B

“…EGFR exon 20 insertions (EGFRex20ins) comprise an uncommon subset of EGFR-activating alterations relatively insensitive to first- and second-generation EGFR…”
Get more information

The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy by Knepper, Todd C, Montesion, Meagan, Russell, Jeffery S, Sokol, Ethan S, Frampton, Garrett M, Miller, Vincent A, Albacker, Lee A, McLeod, Howard L, Eroglu, Zeynep, Khushalani, Nikhil I, Sondak, Vernon K, Messina, Jane L, Schell, Michael J, DeCaprio, James A, Tsai, Kenneth Y, Brohl, Andrew S

“…Merkel cell carcinoma (MCC) is a rare, aggressive cutaneous malignancy, which has demonstrated sensitivity to immune checkpoint inhibitor therapy. Here, we…”
Get full text

Implications of polygenic risk for personalised colorectal cancer screening by Frampton, M.J.E., Law, P., Litchfield, K., Morris, E.J., Kerr, D., Turnbull, C., Tomlinson, I.P., Houlston, R.S.

“…We modelled the utility of applying a personalised screening approach for colorectal cancer (CRC) when compared with standard age-based screening. In this…”
Get full text

A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability and Pan-Tumor Characterization of 1000 Microsatellite Instability–High Cases in 67,000 Patient Samples by Trabucco, Sally E., Gowen, Kyle, Maund, Sophia L., Sanford, Eric, Fabrizio, David A., Hall, Michael J., Yakirevich, Evgeny, Gregg, Jeffrey P., Stephens, Phil J., Frampton, Garrett M., Hegde, Priti S., Miller, Vincent A., Ross, Jeffrey S., Hartmaier, Ryan J., Huang, Shih-Min A., Sun, James X.

“…Microsatellite instability (MSI) is an important biomarker for predicting response to immune checkpoint inhibitor therapy, as emphasized by the recent…”
Get full text

Comprehensive Genomic Profiling of 282 Pediatric Low‐ and High‐Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures by Johnson, Adrienne, Severson, Eric, Gay, Laurie, Vergilio, Jo‐Anne, Elvin, Julia, Suh, James, Daniel, Sugganth, Covert, Mandy, Frampton, Garrett M., Hsu, Sigmund, Lesser, Glenn J., Stogner‐Underwood, Kimberly, Mott, Ryan T., Rush, Sarah Z., Stanke, Jennifer J., Dahiya, Sonika, Sun, James, Reddy, Prasanth, Chalmers, Zachary R., Erlich, Rachel, Chudnovsky, Yakov, Fabrizio, David, Schrock, Alexa B., Ali, Siraj, Miller, Vincent, Stephens, Philip J., Ross, Jeffrey, Crawford, John R., Ramkissoon, Shakti H.

“…Background Pediatric brain tumors are the leading cause of death for children with cancer in the U.S. Incorporating next‐generation sequencing data for both…”
Get full text

The lifetime revision risk of unicompartmental knee arthroplasty by Tay, Mei L, Young, Simon W, Frampton, Christopher M, Hooper, Gary J

“…Unicompartmental knee arthroplasty (UKA) has a higher risk of revision than total knee arthroplasty (TKA), particularly for younger patients. The outcome of…”
Get full text

Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors by Frampton, Garrett M, Ali, Siraj M, Rosenzweig, Mark, Chmielecki, Juliann, Lu, Xinyuan, Bauer, Todd M, Akimov, Mikhail, Bufill, Jose A, Lee, Carrie, Jentz, David, Hoover, Rick, Ou, Sai-Hong Ignatius, Salgia, Ravi, Brennan, Tim, Chalmers, Zachary R, Jaeger, Savina, Huang, Alan, Elvin, Julia A, Erlich, Rachel, Fichtenholtz, Alex, Gowen, Kyle A, Greenbowe, Joel, Johnson, Adrienne, Khaira, Depinder, McMahon, Caitlin, Sanford, Eric M, Roels, Steven, White, Jared, Greshock, Joel, Schlegel, Robert, Lipson, Doron, Yelensky, Roman, Morosini, Deborah, Ross, Jeffrey S, Collisson, Eric, Peters, Malte, Stephens, Philip J, Miller, Vincent A

“…Focal amplification and activating point mutation of the MET gene are well-characterized oncogenic drivers that confer susceptibility to targeted MET…”
Get more information

Mutations in the TERC template sequence can be incorporated into the telomeres of human tumors by Sharaf, Radwa, Frampton, Garrett M, Albacker, Lee A

“…Telomerase-mediated lengthening is a mechanism by which some cancer cells avoid senescence-mediated cell cycle arrest due to shortened telomeres. By reverse…”
Get full text